Core Insights - Alumis Inc. is experiencing strong momentum in its development programs, particularly with the ongoing clinical trials for its TYK2 inhibitor ESK-001, which is expected to yield pivotal Phase 3 data for moderate-to-severe plaque psoriasis in early 2026 [2][4] - The company is focused on the anticipated merger with ACELYRIN, which is expected to enhance its clinical pipeline and financial flexibility, creating value for both patients and stockholders [2][4] - Alumis reported a net loss of $99.0 million for Q1 2025, a significant increase from a loss of $49.8 million in Q1 2024, driven by higher research and development expenses [9][19] Recent Highlights - Alumis entered into a collaboration and licensing agreement with Kaken Pharmaceutical for ESK-001 in Japan, receiving an upfront license fee of $20 million and additional near-term co-development payments [4][9] - The merger agreement with ACELYRIN was approved by Alumis stockholders, with the combined company expected to have a pro forma cash position of approximately $737 million as of December 31, 2024, providing a runway for advancing its pipeline [4][9] - The company plans to initiate a Phase 2 clinical trial for A-005 in multiple sclerosis and finalize the clinical development plan for Lonigutamab following the merger [4][9] Financial Results - For the quarter ended March 31, 2025, Alumis reported total revenue of $17.4 million, primarily from license revenue related to the Kaken collaboration [9][19] - Research and development expenses increased to $96.6 million in Q1 2025 from $42.0 million in Q1 2024, reflecting higher costs associated with clinical trials and increased headcount [9][19] - General and administrative expenses rose to $22.3 million in Q1 2025 from $5.6 million in Q1 2024, mainly due to transaction costs related to the merger and personnel-related expenses [9][19] Anticipated Milestones - Key upcoming milestones include topline data for ESK-001 in psoriasis expected in Q1 2026 and Phase 2b data for systemic lupus erythematosus also expected in 2026 [4][9] - The merger with ACELYRIN is anticipated to close in the second quarter of 2025, which is expected to enhance value creation opportunities for stockholders [4][9]

Core Viewpoint - Alumis Inc. has received stockholder approval for its merger with ACELYRIN, INC., marking a significant step towards closing the transaction and enhancing its capabilities in developing therapies for immune-mediated diseases [1][2][3] Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies using a precision approach to improve clinical outcomes for patients with immune-mediated diseases [4] - The company utilizes a proprietary precision data analytics platform to build a pipeline of molecules targeting a wide range of immune-mediated diseases, both as monotherapy and combination therapies [4] - Alumis' leading product candidate, ESK-001, is an oral, selective small molecule inhibitor currently being evaluated for moderate-to-severe plaque psoriasis and systemic lupus erythematosus [4] Merger Details - The merger with ACELYRIN is anticipated to close in the second quarter of 2025, pending the fulfillment of customary closing conditions [3] - Martin Babler, President and CEO of Alumis, expressed gratitude to stockholders for their support and emphasized the goal of maximizing the value of their portfolio post-merger [2] Future Prospects - The merger is expected to provide Alumis with a strengthened financial foundation, enabling the advancement of breakthroughs in the treatment of immune-mediated diseases [2]

Core Insights - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases using a precision approach to enhance clinical outcomes and patient quality of life [3] Company Overview - Alumis is leveraging a proprietary precision data analytics platform to build a pipeline of molecules aimed at treating a variety of immune-mediated diseases, either as monotherapy or in combination therapies [3] - The company's lead product candidate, ESK-001, is an oral, highly selective small molecule that acts as an allosteric inhibitor of tyrosine kinase 2 (TYK2), currently under evaluation for moderate-to-severe plaque psoriasis and systemic lupus erythematosus [3] - Additionally, Alumis is developing A-005, a CNS-penetrant allosteric TYK2 inhibitor targeting neuroinflammatory and neurodegenerative diseases [3] - The company is incubated by Foresite Labs and is led by a team experienced in small-molecule drug development for immune-mediated diseases, aiming to pioneer a precision approach to drug development [3] Upcoming Events - Martin Babler, President and CEO of Alumis, will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on March 11, 2025, at 10:40 am ET [1]